Clinical Trial Update: Phase 1b/2 Trial Using Lapatinib, Everolimus and Capecitabine for Treatment of HER-2 Positive Breast Cancer With CNS Metastasis [Phase 1, Phase 2]

View source ↗

Summary

Phase 1b/2 trial evaluating lapatinib, everolimus, and capecitabine for HER2-positive breast cancer with CNS metastases has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Central Nervous System Metastases

Drugs mentioned

• Capecitabine (capecitabine)
• Everolimus (everolimus)
• Lapatinib (Lapatinib)

Snippet

Sponsor: Jonsson Comprehensive Cancer Center | Conditions: Central Nervous System Metastases, HER2-positive Breast Cancer | Phase 1, Phase 2 | Status: COMPLETED